Paul Tudor Jones Seagen Inc. Transaction History

Tudor Investment Corp Et Al

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	BUY	$191.51 - $216.16 $159 Million - $180 Million	831,320 Added 244.5%	1,171,324 $248 Million
Q2 2023 Aug 14, 2023	BUY	$187.64 - $206.25 $63.8 Million - $70.1 Million	340,004 New	340,004 $65.4 Million
Q3 2022 Nov 14, 2022	SELL	$135.27 - $180.11 $691,500 - $920,722	-5,112 Reduced 52.52%	4,622 $632,000
Q2 2022 Aug 15, 2022	SELL	$108.81 - $179.33 $2.3 Million - $3.78 Million	-21,098 Reduced 68.43%	9,734 $1.72 Million
Q1 2022 May 16, 2022	SELL	$119.61 - $157.85 $868,966 - $1.15 Million	-7,265 Reduced 19.07%	30,832 $4.44 Million
Q4 2021 Feb 14, 2022	BUY	$142.57 - $190.86 $5.43 Million - $7.27 Million	38,097 New	38,097 $5.89 Million
Q2 2021 Aug 16, 2021	SELL	$135.08 - $161.1 $2.51 Million - $2.99 Million	-18,558 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$137.51 - $190.8 $2.55 Million - $3.54 Million	18,558 New	18,558 $2.58 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.